TABLE 7.
Baseline characteristics of subjects with HBV not on NAs who did not meet the 2018 AASLD HBV treatment guidelines and developed HCC (no NA/HCC), and subjects with HBV on NAs who developed HCC (NA/HCC) at time of HCC diagnosis
| Factor | No NA/HCC (n = 133) Median (IQR) | NA/HCC (n = 209) Median (IQR) | p‐Value |
|---|---|---|---|
| ALT (IU/L) | 60 (42–117) | 56 (39–99) | 0.5 |
| HBV DNA (mIU/ml) | Undetected (undetected–undetected) | 20 (undetected–51) | <0.001 |
| ALP (U/L) | 129 (93–194) | 108 (81–147) | 0.001 |
| AST (IU/L) | 64 (40–115) | 50 (31–128) | 0.1 |
| TB (mg/dl) | 1.2 (0.7–1.8) | 0.9 (0.6–1.4) | 0.02 |
| INR | 1.2 (1.1–1.4) | 1.2 (1.1–1.3) | 0.02 |
| NAs (mmol/L) | 137 (135–139) | 138 (136–140) | 0.1 |
| Platelets (K/ul) | 117 (88–170) | 139 (101–198) | 0.003 |
| Albumin (g/dl) | 3.4 (2.8–3.7) | 3.6 (3–4.1) | <0.001 |